Overview

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma
Phase:
PHASE1
Details
Lead Sponsor:
Cullinan Therapeutics Inc.